Month: November 2022

Letter from 19 groups asking HHS to take action on the ​request that HHS use the federal government rights in patents on the prostate drug enzalutamide, marketed by Astellas under the brand name Xtandi.

Posted on by James Love

Warning: call_user_func_array() expects parameter 1 to be a valid callback, function 'wp_embed_excerpt_more' not found or invalid function name in /home/keionli38/public_html/wp-includes/class-wp-hook.php on line 341

Attached is a letter from 19 groups asking HHS Secretary Xavier Becerra to take action on the ​request that HHS use the federal government rights in patents on the prostate drug enzalutamide, marketed by Astellas under the brand name Xtandi.…

Pandemic Treaty negotiations: The Conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at its third meeting

Posted on by KEI Staff

Warning: call_user_func_array() expects parameter 1 to be a valid callback, function 'wp_embed_excerpt_more' not found or invalid function name in /home/keionli38/public_html/wp-includes/class-wp-hook.php on line 341

This is what delegates will be discussing at the next INB meeting the week of December 5, 2022, in Geneva. ADVANCE_for_16_November_A_INB3_3_E From the document: “In preparing a conceptual zero draft, the Bureau started by integrating the above-mentioned input into the…

Letter to Secretary of HHS Xavier Becerra regarding Xtandi march-in case from Robert Sachs and Clare Love

Posted on by James Love

Warning: call_user_func_array() expects parameter 1 to be a valid callback, function 'wp_embed_excerpt_more' not found or invalid function name in /home/keionli38/public_html/wp-includes/class-wp-hook.php on line 341

SecBecerra-18Nov2022-Sachs-Love-Xtandi November 18, 2022 Xavier Becerra Secretary Department of Health & Human Services Washington, DC Via Email: xavier.becerra@hhs.gov Dear Secretary Becerra: Today marks the one-year anniversary since the undersigned prostate cancer patients petitioned the Department of Health & Human Services…

KEI asks WHO to include risdiplam, treatment for Spinal Muscular Atrophy, on the Essential Medicines List (EML)

Posted on by KEI Staff

Warning: call_user_func_array() expects parameter 1 to be a valid callback, function 'wp_embed_excerpt_more' not found or invalid function name in /home/keionli38/public_html/wp-includes/class-wp-hook.php on line 341

KEI has petitioned the World Health Organization (WHO) to include risdiplam, a drug to treat Spinal Muscular Atrophy (SMA), on its Essential Medicines List (EML), in a category for products that should be accessible if available at affordable prices. Risdiplam-EML-2022-KEI